source
- Apnimed upsizes IPO to $192 million to fund launch of oral sleep‑apnea drugApnimed, a Massachusetts‑based biotech, announced an upsized initial public offering that now includes 12 million shares priced at $16 each, generating $192 million in gross proceeds. This amount e…
- FDA advisory panel backs experimental Replimune melanoma therapy after two prior rejectionsAn FDA advisory committee voted 10‑to‑3 to recommend the use of an experimental Replimune treatment for patients with advanced melanoma. The panel’s recommendation marks a shift after the agency p…